Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T13:36:31.237Z.
Calculation as of: 2026-10-06T13:36:31.237Z.
Quote observation: 2026-10-06T13:34:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Electra Therapeutics Inc.
Market Cap
$202.16M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$194.51M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$184.12M
Price/FCF Ratio
N/A
TTM Avg
81.50
3Y Avg
61.57
5Y Avg
61.57
Market Cap
$180.08M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$175.27M
Price/FCF Ratio
N/A
TTM Avg
396.65
3Y Avg
396.65
5Y Avg
396.65
Market Cap
$230.09M
Price/FCF Ratio
N/A
TTM Avg
9.31
3Y Avg
9.38
5Y Avg
9.38
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Electra Therapeutics Inc. (ETRA) | $202.16M | N/A | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $198.09M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $194.51M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $219.84M | N/A | N/A | N/A | N/A |
| Journey Medical Corporation (DERM)vs › | $184.12M | N/A | 81.50 | 61.57 | 61.57 |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.08M | N/A | N/A | N/A | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $177.91M | N/A | N/A | N/A | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $175.27M | N/A | 396.65 | 396.65 | 396.65 |
| Keros Therapeutics, Inc. (KROS)vs › | $230.09M | N/A | 9.31 | 9.38 | 9.38 |
| Alector, Inc. (ALEC)vs › | $230.93M | N/A | 3.22 | 3.23 | 4.48 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
